Trial_ID,stats_name,n_Randomized,All_cause_mortality_events_D1428,Year,ROB_6_mortality_D28,rob
110,Convalescent plasma,179,7,2021,Low,l
110,Standard care/Placebo,171,14,2021,Low,l
111,Interferon beta-1b,40,2,2020,Some concerns,m
111,Standard care/Placebo,40,6,2020,Some concerns,m
112,Hydrocortisone,76,11,2020,Low,l
112,Standard care/Placebo,73,20,2020,Low,l
113,Fixed-dose hydrocortisone,143,41,2020,Some concerns,m
113,Standard care/Placebo,108,33,2020,Some concerns,m
114,Dexamethasone,151,85,2020,Some concerns,m
114,Standard care/Placebo,148,91,2020,Some concerns,m
123,Convalescent plasma,235,34,2020,Some concerns,m
123,Standard care/Placebo,229,31,2020,Some concerns,m
125,Tocilizumab,301,58,2022,Low,l
125,Standard care/Placebo,151,28,2022,Low,l
131,rhG-CSF,100,3,2020,Some concerns,m
131,Standard care/Placebo,100,12,2020,Some concerns,m
148,Convalescent plasma,28,5,2021,Low,l
148,Late CP,30,2,2021,Low,l
164,Interferon beta-1a,2063,243,2020,Low,l
164,Standard care/Placebo,2064,216,2020,Low,l
167,Methylprednisolone,24,13,2020,Some concerns,m
167,Standard care/Placebo,23,13,2020,Some concerns,m
168,Dexamethasone,7,2,2020,Low,l
168,Standard care/Placebo,12,2,2020,Low,l
169,Tocilizumab,60,2,2020,Some concerns,m
169,Standard care/Placebo,66,1,2020,Some concerns,m
171,Tocilizumab,64,7,2020,Some concerns,m
171,Standard care/Placebo,67,8,2020,Some concerns,m
173,Tocilizumab,161,9,2020,Low,l
173,Standard care/Placebo,82,3,2020,Low,l
174,Hydrocortisone,15,6,2020,Low,l
174,Standard care/Placebo,14,2,2020,Low,l
180,Tocilizumab,259,26,2020,Low,l
180,Standard care/Placebo,129,11,2020,Low,l
182,Convalescent plasma,15,3,2022,Some concerns,m
182,Standard plasma,16,1,2022,Some concerns,m
195,IV Ig,52,24,2020,Some concerns,m
195,Standard care/Placebo,32,14,2020,Some concerns,m
200,Convalescent plasma,20,1,2021,Some concerns,m
200,Standard care/Placebo,20,2,2021,Some concerns,m
205,Convalescent plasma,80,2,2021,Low,l
205,Standard care/Placebo,80,4,2021,Low,l
206,Convalescent plasma,228,25,2020,Low,l
206,Standard care/Placebo,106,12,2020,Low,l
209,Convalescent plasma,40,10,2022,High,h
209,Standard care/Placebo,40,14,2022,High,h
211,Itolizumab,22,1,2021,Some concerns,m
211,Standard care/Placebo,10,3,2021,Some concerns,m
232,Tocilizumab,366,98,2021,Some concerns,m
232,Sarilumab,48,10,2021,Some concerns,m
232,Standard care/Placebo,412,142,2021,Some concerns,m
24,Ruxolitinib,22,0,2020,Some concerns,m
24,Standard care/Placebo,21,3,2020,Some concerns,m
244,Interferon beta-1a High,83,34,2021,Some concerns,m
244,Interferon beta-1a,85,31,2021,Some concerns,m
245,INF-beta-1a+INF-beta-1b,40,10,2021,Some concerns,m
245,Interferon beta-1b,20,6,2021,Some concerns,m
245,Interferon beta-1a,20,4,2021,Some concerns,m
245,Standard care/Placebo,20,9,2021,Some concerns,m
25,Interferon beta-1a,46,8,2020,High,h
25,Standard care/Placebo,46,17,2020,High,h
250,Tocilizumab,65,14,2021,Some concerns,m
250,Standard care/Placebo,64,6,2021,Some concerns,m
252,Anakinra,59,13,2021,Low,l
252,Standard care/Placebo,57,13,2021,Low,l
254,Methylprednisolone,43,0,2021,Some concerns,m
254,Standard care/Placebo,43,1,2021,Some concerns,m
26,Convalescent plasma,52,8,2020,Some concerns,m
26,Standard care/Placebo,51,12,2020,Some concerns,m
261,Methylprednisolone,47,8,2021,Some concerns,m
261,Dexamethasone,46,15,2021,Some concerns,m
267,Sarilumab,334,30,2021,Low,l
267,Standard care/Placebo,86,7,2021,Low,l
274,Tocilizumab,2022,621,2021,Low,l
274,Standard care/Placebo,2094,729,2021,Low,l
277,INM005,120,8,2021,Low,l
277,Standard care/Placebo,125,14,2021,Low,l
280,Convalescent plasma,21,1,2020,,
280,Standard care/Placebo,28,8,2020,,
282,Dexamethasone,25,16,2021,Some concerns,m
282,Standard care/Placebo,25,15,2021,Some concerns,m
283,IV Ig,50,0,2021,Some concerns,m
283,Standard care/Placebo,50,1,2021,Some concerns,m
295,Tocilizumab,90,13,2021,Some concerns,m
295,Standard care/Placebo,90,15,2021,Some concerns,m
296,Convalescent plasma,5795,1399,2021,Low,l
296,Standard care/Placebo,5763,1408,2021,Low,l
300,Convalescent plasma,150,19,2021,Low,l
300,Standard plasma,73,18,2021,Low,l
304,Mavrilimumab,21,1,2021,Some concerns,m
304,Standard care/Placebo,19,3,2021,Some concerns,m
311,TD-0903,7,0,2021,Some concerns,m
311,Standard care/Placebo,6,2,2021,Some concerns,m
321,Thalidomide,30,4,2021,High,h
321,Standard care/Placebo,30,6,2021,High,h
323,Canakinumab,29,4,2021,Low,l
323,Standard care/Placebo,16,3,2021,Low,l
326,CERC-002,41,3,2021,Low,l
326,Standard care/Placebo,42,6,2021,Low,l
333,Convalescent plasma,59,14,2021,Low,l
333,Standard plasma,15,4,2021,Low,l
334,Otilimab,403,64,2021,Low,l
334,Standard care/Placebo,403,74,2021,Low,l
34,Dexamethasone,2104,482,2021,Low,l
34,Standard care/Placebo,4321,1110,2021,Low,l
344,Tocilizumab,74,60,2021,Some concerns,m
344,Dexamethasone,75,45,2021,Some concerns,m
348,PNB001,20,1,2021,Some concerns,m
348,Standard care/Placebo,20,2,2021,Some concerns,m
352,Baricitinib,764,62,2021,Low,l
352,Standard care/Placebo,761,100,2021,Low,l
353,Tocilizumab,174,21,2022,Low,l
353,Standard care/Placebo,180,34,2022,Low,l
354,Lenzilumab,261,24,2021,Some concerns,m
354,Standard care/Placebo,259,34,2021,Some concerns,m
356,Tocilizumab,20,5,2021,High,h
356,Standard care/Placebo,20,4,2021,High,h
357,Convalescent plasma,53,8,2021,Some concerns,m
357,Standard care/Placebo,52,14,2021,Some concerns,m
363,Sarilumab,367,102,2022,Some concerns,m
363,Standard care/Placebo,90,19,2022,Some concerns,m
365,Anakinra,412,13,2021,Low,l
365,Standard care/Placebo,194,13,2021,Low,l
377,Sarilumab,1044,264,2022,Some concerns,m
377,Standard care/Placebo,286,64,2022,Some concerns,m
398,C-IVIG,40,10,2021,Some concerns,m
398,Standard care/Placebo,10,6,2021,Some concerns,m
399,Namilumab,57,6,2021,Some concerns,m
399,Infliximab,35,4,2021,Some concerns,m
399,Standard care/Placebo,54,10,2021,Some concerns,m
400,Convalescent plasma,1084,401,2021,Low,l
400,Standard care/Placebo,916,347,2021,Low,l
405,Tofacitinib,144,4,2021,Low,l
405,Standard care/Placebo,145,8,2021,Low,l
406,Imatinib,204,15,2021,Some concerns,m
406,Standard care/Placebo,196,27,2021,Some concerns,m
411,Hydrocortisone,16,6,2021,Low,l
411,Standard care/Placebo,14,2,2021,Low,l
425,Convalescent plasma,627,141,2021,Some concerns,m
425,Standard care/Placebo,313,63,2021,Some concerns,m
431,Convalescent plasma,80,18,2021,Some concerns,m
431,Standard care/Placebo,80,13,2021,Some concerns,m
440,Canakinumab,227,12,2021,Low,l
440,Standard care/Placebo,227,16,2021,Low,l
442,Secukinumab,25,1,2022,Some concerns,m
442,Standard care/Placebo,25,1,2022,Some concerns,m
448,Sarilumab,68,8,2021,Some concerns,m
448,Standard care/Placebo,80,14,2021,Some concerns,m
449,Sarilumab,50,14,2022,Some concerns,m
449,Standard care/Placebo,41,11,2022,Some concerns,m
450,Sarilumab,20,2,2022,Some concerns,m
450,Standard care/Placebo,10,0,2022,Some concerns,m
452,Sarilumab,99,2,2021,Low,l
452,Standard care/Placebo,102,2,2021,Low,l
463,Convalescent plasma,69,10,2021,Some concerns,m
463,Standard care/Placebo,67,8,2021,Some concerns,m
467,Tocilizumab,10,0,2021,Low,l
467,Standard care/Placebo,11,2,2021,Low,l
468,Tocilizumab,20,0,2021,Low,l
468,Standard care/Placebo,8,2,2021,Low,l
469,Tocilizumab,51,8,2022,Some concerns,m
469,Standard care/Placebo,46,10,2022,Some concerns,m
470,Tocilizumab,59,1,2022,Some concerns,m
470,Standard care/Placebo,29,0,2022,Some concerns,m
472,Tocilizumab,37,11,2021,High,h
472,Standard care/Placebo,17,8,2021,High,h
473,Tocilizumab,22,2,2021,Low,l
473,Standard care/Placebo,27,2,2021,Low,l
483,TCZ+Dex,226,15,2021,Some concerns,m
483,Dexamethasone,227,19,2021,Some concerns,m
484,Adalimumab,34,4,2021,Some concerns,m
484,Standard care/Placebo,34,4,2021,Some concerns,m
515,Levilimab,103,4,2021,Some concerns,m
515,Standard care/Placebo,103,4,2021,Some concerns,m
516,Opaganib,23,3,2022,Some concerns,m
516,Standard care/Placebo,19,3,2022,Some concerns,m
523,Sargramostim,40,2,2021,Some concerns,m
523,Standard care/Placebo,41,2,2021,Some concerns,m
531,Baricitinib,51,20,2022,Low,l
531,Standard care/Placebo,50,29,2022,Low,l
546,Tocilizumab,82,9,2021,Low,l
546,Siltuximab,76,10,2021,Low,l
546,Standard care/Placebo,72,7,2021,Low,l
554,C-IVIG,30,1,2021,Low,l
554,Standard care/Placebo,30,1,2021,Low,l
555,Anakinra,15,5,2021,Some concerns,m
555,Standard care/Placebo,15,7,2021,Some concerns,m
558,IV Ig,69,24,2021,Low,l
558,Standard care/Placebo,77,20,2021,Low,l
559,Convalescent plasma,41,2,2021,Low,l
559,Standard care/Placebo,39,10,2021,Low,l
568,Convalescent plasma,241,14,2021,Low,l
568,Standard care/Placebo,246,19,2021,Low,l
571,Clazakizumab,8,1,2021,Some concerns,m
571,Standard care/Placebo,9,1,2021,Some concerns,m
574,Convalescent plasma,18,2,2021,Some concerns,m
574,Standard care/Placebo,15,3,2021,Some concerns,m
58,IV Ig,17,1,2020,Some concerns,m
58,Standard care/Placebo,17,3,2020,Some concerns,m
583,Convalescent plasma,468,59,2021,Low,l
583,Standard care/Placebo,473,71,2021,Low,l
59,Methylprednisolone,209,79,2020,Low,l
59,Standard care/Placebo,207,80,2020,Low,l
592,Sarilumab,79,4,2021,Some concerns,m
592,Standard care/Placebo,39,3,2021,Some concerns,m
593,Auxora,143,10,2022,Some concerns,m
593,Standard care/Placebo,141,23,2022,Some concerns,m
607,Ruxolitinib,287,9,2022,Some concerns,m
607,Standard care/Placebo,145,3,2022,Some concerns,m
611,Convalescent plasma,63,7,2022,Some concerns,m
611,Standard care/Placebo,95,12,2022,Some concerns,m
617,Tocilizumab,21,2,2021,Some concerns,m
617,Dexamethasone,21,13,2021,Some concerns,m
626,Methylprednisolone,19,1,2022,High,h
626,Standard care/Placebo,22,1,2022,High,h
628,Convalescent plasma,37,8,2022,Some concerns,m
628,Standard care/Placebo,73,18,2022,Some concerns,m
638,C-IVIG,301,18,2022,Some concerns,m
638,Standard care/Placebo,292,22,2022,Some concerns,m
640,Avdoralimab,103,20,2022,Low,l
640,Standard care/Placebo,104,12,2022,Low,l
649,Convalescent plasma,52,11,2022,Low,l
649,Standard care/Placebo,51,13,2022,Low,l
652,Sarilumab,20,6,2022,Low,l
652,Standard care/Placebo,30,2,2022,Low,l
658,Baricitinib,4148,514,2022,Low,l
658,Standard care/Placebo,4008,546,2022,Low,l
659,Ruxolitinib,164,90,2022,Low,l
659,Standard care/Placebo,47,36,2022,Low,l
665,Gimsilumab,114,32,2022,Low,l
665,Standard care/Placebo,113,26,2022,Low,l
673,Methylprednisolone,152,15,2022,Low,l
673,Standard care/Placebo,152,18,2022,Low,l
676,Convalescent plasma,200,42,2022,Some concerns,m
676,Standard care/Placebo,200,37,2022,Some concerns,m
678,Dupilumab,19,1,2022,Low,l
678,Standard care/Placebo,21,3,2022,Low,l
679,Convalescent plasma,32,4,2022,Some concerns,m
679,Standard care/Placebo,11,8,2022,Some concerns,m
680,C-IVIG,10,0,2022,Some concerns,m
680,IV Ig,8,3,2022,Some concerns,m
682,CP-High titer,14,2,2022,Some concerns,m
682,Convalescent plasma,41,10,2022,Some concerns,m
683,Clazakizumab,78,19,2022,Low,l
683,Standard care/Placebo,74,20,2022,Low,l
69,Vilobelimab,15,2,2020,Some concerns,m
69,Standard care/Placebo,15,4,2020,Some concerns,m
690,Reparixin,37,1,2022,Some concerns,m
690,Standard care/Placebo,19,3,2022,Some concerns,m
691,RPH-104,124,14,2022,Low,l
691,Olokizumab,124,9,2022,Low,l
691,Standard care/Placebo,124,6,2022,Low,l
696,hzVSF-v13,45,4,2022,Some concerns,m
696,Standard care/Placebo,19,3,2022,Some concerns,m
699,Sargramostim,79,9,2022,High,h
699,Standard care/Placebo,44,6,2022,High,h
700,Garadacimab,63,11,2022,Low,l
700,Standard care/Placebo,61,11,2022,Low,l
701,Zanubrutinib,30,2,2022,Low,l
701,Standard care/Placebo,33,4,2022,Low,l
702,Acalabrutinib,31,2,2022,Some concerns,m
702,Standard care/Placebo,31,2,2022,Some concerns,m
707,Baricitinib,125,40,2022,Low,l
707,Tocilizumab,126,50,2022,Low,l
708,Opaganib,237,36,2022,Some concerns,m
708,Standard care/Placebo,238,38,2022,Some concerns,m
712,Astegolimab,130,19,2022,Low,l
712,Efmarodocokin alfa,132,17,2022,Low,l
712,Standard care/Placebo,134,15,2022,Low,l
721,Convalescent plasma,50,6,2022,Some concerns,m
721,Standard care/Placebo,51,2,2022,Some concerns,m
724,Anakinra,40,0,2022,Some concerns,m
724,Standard care/Placebo,40,1,2022,Some concerns,m
726,Convalescent plasma,495,89,2022,Low,l
726,Standard care/Placebo,479,80,2022,Low,l
730,Methylprednisolone,73,9,2022,Some concerns,m
730,Dexamethasone,70,12,2022,Some concerns,m
735,Pamrevlumab,11,3,2022,Low,l
735,Standard care/Placebo,11,2,2022,Low,l
741,TNF/EMT+DEX,71,4,2022,Some concerns,m
741,TNF/EMT+DEX+Barictinib,70,2,2022,Some concerns,m
741,Barictinib+DEX,75,1,2022,Some concerns,m
741,Dexamethasone,71,3,2022,Some concerns,m
745,Baricitinib,142,14,2022,Low,l
745,Standard care/Placebo,142,18,2022,Low,l
746,Anakinra,37,9,2022,Some concerns,m
746,Standard care/Placebo,34,3,2022,Some concerns,m
747,Tocilizumab+Remdesivir,104,26,2022,Some concerns,m
747,Dexamethasone,104,32,2022,Some concerns,m
764,Convalescent plasma,60,7,2022,Low,l
764,Standard care/Placebo,60,12,2022,Low,l
765,Convalescent plasma,35,3,2022,Some concerns,m
765,Standard care/Placebo,40,4,2022,Some concerns,m
766,TD-0903,106,6,2022,Low,l
766,Standard care/Placebo,104,13,2022,Low,l
767,Vilobelimab,178,54,2022,Some concerns,m
767,Standard care/Placebo,191,77,2022,Some concerns,m
770,Sirukumab,140,18,2022,Low,l
770,Standard care/Placebo,72,13,2022,Low,l
771,Lanadelumab,28,8,2022,Low,l
771,Standard care/Placebo,34,9,2022,Low,l
772,Convalescent plasma,326,29,2021,Some concerns,m
772,Standard care/Placebo,163,12,2021,Some concerns,m
775,Otilimab,175,63,2022,Some concerns,m
775,Standard care/Placebo,175,70,2022,Some concerns,m
778,Convalescent plasma,20,3,2022,Some concerns,m
778,Standard care/Placebo,10,2,2022,Some concerns,m
800,Apremilast,194,34,2022,Low,l
800,Standard care/Placebo,190,33,2022,Low,l
85,Methylprednisolone,35,7,2020,High,h
85,Standard care/Placebo,29,5,2020,High,h
92,Auxora,17,2,2020,Some concerns,m
92,Standard care/Placebo,9,2,2020,Some concerns,m
